Roles of PPAR activation in cancer therapeutic resistance: Implications for combination therapy and drug development

Author:

Zhang YanxiaORCID,Xiao BinORCID,Liu Yunduo,Wu ShunhongORCID,Xiang Qin,Xiao Yuhan,Zhao Junxiu,Yuan Ruanfei,Xie KepingORCID,Li LinhaiORCID

Publisher

Elsevier BV

Subject

Pharmacology

Reference338 articles.

1. Reduced expression of peroxisome proliferator-activated receptor α in BAL and blood T cells of non-lofgren’s sarcoidosis patients;Abo Al Hayja;J. Inflamm.,2015

2. A cancer cell-intrinsic GOT2-PPARδ axis suppresses antitumor immunity;Abrego;Cancer Discov.,2022

3. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth;Abu Aboud;Am. J. Physiol. Cell Physiol.,2015

4. PPARα mediates sunitinib resistance via NF-κB activation in clear cell renal cell carcinoma;Aimudula;Int. J. Clin. Exp. Pathol.,2018

5. Mechanisms of acquired tumor drug resistance;Aleksakhina;Biochim. Biophys. Acta Rev. Canc,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3